Pharma Services Network

Since 2003, Pharma Services Network has been helping pharmaceutical, biotech, and device sponsors from around the world to identify, qualify, and engage with service providers ideally suited to their needs. We have in-depth knowledge of Internationally based CROs, Regulatory Consultants, and a host of other strategic service providers.

C-Suite On Deck

Responsive image

Feature market insights and perspectives from top C-Level executives, elite technology influencers and thought leaders from your company here. This signature initiative has garnered immense support...

Contact Us

Events

Related News

PHARMACY MARKET

ENTOS PHARMACEUTICALS ANNOUNCES SENIOR LEADERSHIP APPOINTMENTS TO EXPAND EXECUTIVE TEAM AND ACCELERATE GROWTH

Entos Pharmaceuticals | March 07, 2022

news image

EDMONTON, Alberta Entos Pharmaceuticals a clinical-stage biotechnology company developing genetic medicines with its Fusogenix proteolipid vehicle (PLV) nucleic acid delivery platform, today announced two executive-level appointments, Dr. Steve Chen as Chief Medical Officer (CMO) and Jason Ding as Chief Business Officer (CBO). Dr. Steve Chen brings over 20 years of academic research and pharmaceutical biotechnology experience across multiple therapeutic areas to Entos. He will be ...

Read More

BUSINESS INSIGHTS

NOVABAY PHARMACEUTICALS COLLABORATES WITH HARROW HEALTH’S IMPRIMISRX TO PROMOTE PRESCRIPTION AVENOVA

NovaBay Pharmaceuticals | July 20, 2021

news image

NovaBay Pharmaceuticals, Inc., a pharmaceutical firm focused on commercializing Avenova for the eye care market, has announced a collaboration with ImprimisRx, one of the nation's top ophthalmology-focused pharmaceutical companies, to promote prescription Avenova. ImprimisRx, a wholly-owned subsidiary of Harrow Health, Inc., will offer national sales, marketing, and distribution support for NovaBay's FDA-cleared 0.01% hypochlorous acid Avenova in 40 ml bottles. Avenova is a clinically ap...

Read More

GSK, VIR USE CRISPR, ARTIFICIAL INTELLIGENCE TO FIND COVID-19 CURE

PharmaNewsIntelligence | April 07, 2020

news image

GSK is partnering with Vir Biotechnology to use CRISPR and artificial intelligence to identify anti-viral compounds that can treat coronaviruses, including COVID-19. GlaxoSmithKline (GSK) and Vir Biotechnology recently announced a collaboration to enhance COVID-19 drug discovery through the use of CRISPR and artificial intelligence.For more coronavirus updates, visit our resource page, updated twice daily by Xtelligent Healthcare Media. The partnership will initially focus on accelerating the de...

Read More

BUSINESS INSIGHTS

ACTINIUM PHARMACEUTICALS, INC. AND IMMEDICA HAVE SIGNED A COMMERCIALIZATION AGREEMENT FOR IOMAB-B (131I APAMISTAMAB)APAMISTAMAB)

Actinium Pharmaceuticals, Inc. | April 13, 2022

news image

Actinium Pharmaceuticals, Inc., a leader developing targeted radiotherapies for patients and Immedica Pharma AB announced that they signed a license and supply agreement for Iomab-B. It is being developed for targeted conditioning to facilitate bone marrow with topline data expected in the third quarter of 2022. For individuals with active, relapsed, or refractory acute myeloid leukemia, BMT is the only possibly curative therapy option. "Immedica has est...

Read More
news image

PHARMACY MARKET

ENTOS PHARMACEUTICALS ANNOUNCES SENIOR LEADERSHIP APPOINTMENTS TO EXPAND EXECUTIVE TEAM AND ACCELERATE GROWTH

Entos Pharmaceuticals | March 07, 2022

EDMONTON, Alberta Entos Pharmaceuticals a clinical-stage biotechnology company developing genetic medicines with its Fusogenix proteolipid vehicle (PLV) nucleic acid delivery platform, today announced two executive-level appointments, Dr. Steve Chen as Chief Medical Officer (CMO) and Jason Ding as Chief Business Officer (CBO). Dr. Steve Chen brings over 20 years of academic research and pharmaceutical biotechnology experience across multiple therapeutic areas to Entos. He will be ...

Read More
news image

BUSINESS INSIGHTS

NOVABAY PHARMACEUTICALS COLLABORATES WITH HARROW HEALTH’S IMPRIMISRX TO PROMOTE PRESCRIPTION AVENOVA

NovaBay Pharmaceuticals | July 20, 2021

NovaBay Pharmaceuticals, Inc., a pharmaceutical firm focused on commercializing Avenova for the eye care market, has announced a collaboration with ImprimisRx, one of the nation's top ophthalmology-focused pharmaceutical companies, to promote prescription Avenova. ImprimisRx, a wholly-owned subsidiary of Harrow Health, Inc., will offer national sales, marketing, and distribution support for NovaBay's FDA-cleared 0.01% hypochlorous acid Avenova in 40 ml bottles. Avenova is a clinically ap...

Read More
news image

GSK, VIR USE CRISPR, ARTIFICIAL INTELLIGENCE TO FIND COVID-19 CURE

PharmaNewsIntelligence | April 07, 2020

GSK is partnering with Vir Biotechnology to use CRISPR and artificial intelligence to identify anti-viral compounds that can treat coronaviruses, including COVID-19. GlaxoSmithKline (GSK) and Vir Biotechnology recently announced a collaboration to enhance COVID-19 drug discovery through the use of CRISPR and artificial intelligence.For more coronavirus updates, visit our resource page, updated twice daily by Xtelligent Healthcare Media. The partnership will initially focus on accelerating the de...

Read More
news image

BUSINESS INSIGHTS

ACTINIUM PHARMACEUTICALS, INC. AND IMMEDICA HAVE SIGNED A COMMERCIALIZATION AGREEMENT FOR IOMAB-B (131I APAMISTAMAB)APAMISTAMAB)

Actinium Pharmaceuticals, Inc. | April 13, 2022

Actinium Pharmaceuticals, Inc., a leader developing targeted radiotherapies for patients and Immedica Pharma AB announced that they signed a license and supply agreement for Iomab-B. It is being developed for targeted conditioning to facilitate bone marrow with topline data expected in the third quarter of 2022. For individuals with active, relapsed, or refractory acute myeloid leukemia, BMT is the only possibly curative therapy option. "Immedica has est...

Read More